Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
100actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-11 | actual | When the study began enrolling |
| Primary completion | 2025-11-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-06 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Melanoma
Interventions
- Biological: Nivolumab + relatlimab
- Biological: Nivolumab + ipilimumab
Primary outcomes
what the primary-completion date above is the date OFParticipant baseline demographics
measured Baseline
Participant baseline clinical characteristics
measured Baseline
Participant treatment history
measured Baseline
Number of doses of index therapies received (neoadjuvant therapies)
measured Day 1
Types of surgeries received for melanoma after the index date
measured Up to 42-months
Date of last radiation received for melanoma after the index date
measured Up to 42-months
Types of regimens received for melanoma post-surgery in the adjuvant setting
measured Up to 42-months
Number of doses of adjuvant therapies received (post-surgery)
measured Up to 42-months
Dose modifications received by participants
measured Up to 42-months
Rationale for dose modifications
measured Up to 42-months
Rationale for treatment discontinuation
measured Up to 42-months
Overall survival (OS)
measured Up to 42-months
Time to treatment discontinuation (TTD)
measured Up to 42-months
Duration of treatment (DOT)
measured Up to 42-months
Time from neoadjuvant index treatment to adjuvant therapy
measured Up to 42-months
Time from neoadjuvant index treatment to surgery
measured Up to 42-months
Time from surgery to adjuvant therapy
measured Up to 42-months
Pathologic complete response (PCR)
measured Up to 42-months
Event-free survival (EFS)
measured Up to 42-months
Distant metastasis-free survival (DMFS)
measured Up to 42-months
Participant adverse events (AEs)
measured Up to 42-months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed